2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目，150余项中国研究成果入选SABCS。【肿瘤资讯】从官网获得现有资讯，将入选POSTER session 3的中国研究信息整理如下，以飨读者。
PO3-01-01 Dysregulation of Phenylalanine-tyrosine Metabolic Signaling Pathway and Neoadjuvant Response in HER2-positive Breast Cancer.
作者：Chih Wan Goh，Bingqiu Xiu，Jingyan Xue，Yayun Chi ，Jiong Wu
第一作者单位：Fudan University Shanghai Cancer Center
PO3-02-08 Risk factors and a new predictive nomogram for predicting the Non-sentinel Lymph Node Metastasis in 708 early-stage Breast Cancer Patients with Positive Sentinel Nodes in China.
作者：Zhenchuan Song，Xueyi Zhao，Liu Yang
第一作者单位：Department of Breast Center, The Fourth Hospital Of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
PO3-02-12 Dalpiciclib combination with letrozole as neoadjuvant therapy for HR-positive HER2- negative breast cancer: a single-arm, prospective exploratory clinical study.
作者：Jingruo Li，Yuanting Gu，Chuang Du， Jianhua Zhang，Yingying Zhang，Linfeng Zhang，Nan Wang，Lin Li，Fang Wang， Pengwei Lv，Hong Zong，Xinhong Pei， Bingjian Xue，Yan Wang，Dongcheng Gao
第一作者单位： The First Affiliated Hospital of Zhengzhou University
PO3-04-09 Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
作者：Jin Zhang，Yan Liu，Shichao Zhang
第一作者单位：The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China, Tianjin, China (People's Republic).
PO3-05-10 Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study.
作者：PeiJian Peng，Xiao-Lu Xu，Jin-Cai Zhong，Jin-Hui Ye，Zhi-Hui Wang，Hong Wang，Hong Lin，Cai-Wen Du，Guorong Zou，Jie Ouyang，Ying-Ying Shi，Fei Xu，Geng-Sheng Yu ，Yong-Kui Lu，Yong-Xia Wang，Shi-En Cui，Lu-Zhen Li
第一作者单位：The Fifth Affiliated Hospital of Sun Yat-sen University
PO3-06-06 Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE): an open-label, single-arm, phase II study.
作者：Jian Zhang，Yiqun Du，Yanchun Meng ，Yizi Jin，Xuchen Shao，Xiaojun Liu，Yuxin Mu，Yiwei Dou，Yun Liu，Zhimin Shao，Zhen Hu
第一作者单位：Fudan University Shanghai Cancer Center
PO3-06-07 Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial.
作者：huihui Li，Dongdong Zhou，Zeshun Yv，Yuqian Liao，Jie Huang，Shujuan Sun，fangchao zheng，Baojiang Li，Shu Fang，Ling Qiang，Guohua Ren，Bing Bu ，Pengfei Qiu，Xinzhao Wang，Chao Li，Fangli Cao，Qian Shao，Dali Han，Lihua Song ，Baoxuan Zhang，Bingjie Fan，Liang Xu，Xuemei Xie，Xianguang Zhao，Lanping Liu，Wanlong Li，Zhenbo Wang，Changmin Liu，Hui Fu，Xiao Sun，Zhiqiang Shi，Fengxiang Li
第一作者单位：Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, China (People's Republic）
PO3-06-11 Undated analyses from a Phase Ib open-label study of Pucotenlimab (HX008) in combination with gemcitabine and cisplatin as first-line treatment of metastatic triple-negative breast cancer.
作者：Xichun Hu，jun Cao，Biyun wang，Jian Zhang，Leiping Wang，Zhonghua Tao
第一作者单位：Shanghai Cancer Center, Fudan University, China
PO3-07-07 Predictive Modeling for Identifying Breast Cancer Patients Eligible for Axillary Lymph Node Dissection Exemption Following Neoadjuvant Therapy: A Longitudinal MRI-based Radiomics and Deep Learning Features Analysis.
作者：Yushuai Yu，Jialu Yi，Ruiliang Chen，Kaiyan Huang，Jie Zhang，Chuangui Song
第一作者单位：Fujian Cancer Hospital
PO3-08-09 Unique molecular signatures of germline mutations in low expression of human epidermal growth factor receptor 2 (HER2) breast cancer.
作者：Ning Liao，Weiqi Zhang，Liangqiu Liu， Wendy Wu，Siqi Wang，Li Cao，Jianguo Lai， Xueying Zhang，Airong Yang，Yulei Wang， Cheukfai Li，Guochun Zhang，Chongyang Ren ，Lingzhu Wen
第一作者单位：Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
PO3-08-10 Somatic mutations of a multigene panel in Chinese HER2-positive patients undergoing neoadjuvant therapy and impact on prognosis based on TP53 status：a single-institution retrospective cohort.
作者：Min Xiong，Liren Wangxu，Jingyan Xue ，Benlong Yang，Jiong Wu
第一作者单位：Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
PO3-11-09 Cross-cultural adaptation and psychometric validation of lymphedema patient-reported outcome measurements in Chinese breast cancer patients.
作者：Yue Zhou，Bingqiu Xiu，Qi Zhang，Jiong Wu
第一作者单位：Department of Oncology, Fudan University Shanghai Medical College, Shanghai, 200032 China
PO3-14-01 Heterogeneity of tumor immune microenvironment to predict everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2- negative adavanced breast cancer.
作者：Yujing Tan，Fei Ma，Jiayu Wang，Pin Zhang，Binghe Xu ，Liyan Xue，Ying Fan
第一作者单位：Chinese Academy of Medical Sciences and Peking Union Medical College
PO3-14-05 Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+ Breast Cancer.
作者：Ningning Zhang ，Yuxin Huang，Guanwen Wang，Yimei Xiang，Zhouhong Jing，Junjie Zeng，Feng Yu，Xianjun Pan，Wenqi Zhou，Xiaohua Zeng
第一作者单位：Chongqing University Cancer Hospital
PO3-15-01 Overexpression of N-glycosylation related gene OST4 promotes chemotherapy resistance in triple-negative breast cancer.
作者：Wei Wang，Deyue Liu，Shuning Ding，Yan Fang，Jiayi Wu，Li Zhu
第一作者单位：Shanghai General Hospital
PO3-15-06 Identification of a Novel Five Ferroptosis-Related Gene Signature as a Promising Prognostic Model for Breast Cancer.
作者：Tian-cheng Cheng，Jia-hao Wu，Bei Zhu，Lin Zheng，Wei-xian Chen
第一作者单位：Department of Breast Surgery, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China
PO3-18-03 Preoperative single-dose camrelizumab and/or microwave ablation in women with early- stage breast cancer: A randomized window-of-opportunity trial.
作者：wenbin zhou，Hui Xie，qiang ding，Shui Wang
第一作者单位：The First Affiliated Hospital with Nanjing Medical University
PO3-22-09 Implementation of nanoparticle-assisted axillary staging: reduced axillary intervention for patients with node-positive breast cancer following neoadjuvant therapy.
作者：Ruixian Chen，Tao He，Jiqiao Yang，Shan Lu，Yunhao Wu，Chihua Wu，Ruoning Yang，Weijing Liu，Ya Huang ，Xiangyue Meng，Xin Zhao，Qintong Li，Xin Sun，Jing Jing，Jie Chen
第一作者单位：Department of General Surgery, West China Hospital，Sichuan University, Chengdu, China
PO3-23-04 Patient-reported outcomes and complication profiles of implant-based breast reconstruction in patients with postmastectomy radiation therapy.
作者：Jian Liu，Cong Chen ，Honggang Chen，Aizhai Xiang，Ruzhen Zheng，Shufang Hu，Jufeng Guo，Li Qu，Jun Zhou，Jiong Wu
第一作者单位：Hangzhou First People’s Hospital
PO3-24-05 Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer.
作者：Yongmei Yin，Yijia Hua，Ningjun Duan，Chunxiao Sun，Fan Yang
第一作者单位：The First Affiliated Hospital of Nanjing Medical University
PO3-24-10 Losartan enhances the radiosensitivity of triple-negative breast cancer by reshaping the tumor immune microenvironment.
作者：Cuiwei Liu，Xu Wang，Zihan Xia，Yuxi Ma，Yanxia Zhao
第一作者单位：Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
PO3-25-12 Tigecycline-Induced Metabolic Reprogramming and Cytokine Modulation Suppress the Characteristics of Breast Cancer Cells.
作者：Haochen Yu，Lingfeng Tang，Shengchun Liu
第一作者单位：Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, China (People's Republic)
PO3-27-12 Dexamethasone is necessary for preventing acute emesis induced by anthracycline/cyclophosphamide chemotherapy（HELEN-009）: a multicenter, randomized, open- labeled phase 3 trial.
作者：Xiuchun Chen，Jiao Dechuang，Chongjian Zhang，Xianfu Sun，Zhenduo Lu，Lianfang Li，Jianghua Qiao，Chengzheng Wang，Min Yan，Yueqing Feng，Ya Wei，Zhenzhen Liu
第一作者单位：Affiliated Cancer Hospital of Zhengzhou University, China (People's Republic)
PO3-28-04 Ganglioside-Monosialic Acid for Prevention of Peripheral Neuropathy Induced by nab- Paclitaxel in Breast Cancer Patients (HELEN-004): A Randomized, Double-Blind, Phase II Trial.
作者：Zhenduo Lu，Dechuang Jiao，Jianghua Qiao，Hao Zhang，Hao Dai，Xianfu Sun，Min Yan，Yong Zhou，Lianfang Li，Chengzheng Wang，Xiuchun Chen，Zhenzhen Liu
第一作者单位：Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
本文检索了POSTER SESSIONS中第一作者单位为中国单位的研究。如果有任何错误或遗漏，请联系我们进行修改。
SABCS中国之声总览：
Rapid Fire Session: Mini-Oral Presentations、POSTER SPOTLIGHT Session
排版编辑：肿瘤资讯-张薪媛
苏公网安备 32059002004080号
